The ‘BPCIA’ the U.S. plays the worst policy to the Korean biosimilarindustry

Facing enforcement ofthe Korea-US FTA’s (Free Trade Agreement) Patent Linkage System within a month, needs of active responses of biosimilar manufacturers and the government have been suggested.

The political and systematical issues of global and domestic biosimilarsare recognition on acceptance over generic substitutions of interchangeable products and biosimilars based on the FDA’s BPCIA (Bi...